SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders. |
Drug Type Small molecule drug |
Synonyms Cipralex, Entact, Escitalopram + [17] |
Target |
Action antagonists, inhibitors |
Mechanism 5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (07 May 2002), |
Regulation- |
Molecular FormulaC22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS Registry219861-08-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02567 | Escitalopram Oxalate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Phobia, Social | Japan | 20 Nov 2015 | |
Phobia, Social | Japan | 20 Nov 2015 | |
Phobia, Social | Japan | 20 Nov 2015 | |
Phobia, Social | Japan | 20 Nov 2015 | |
Depressive Disorder | China | 31 Aug 2005 | |
Panic Disorder | China | 31 Aug 2005 | |
Generalized anxiety disorder | United States | 18 Dec 2003 | |
Anxiety Disorders | Austria | 07 May 2002 | |
Anxiety Disorders | Belgium | 07 May 2002 | |
Anxiety Disorders | Cyprus | 07 May 2002 | |
Anxiety Disorders | Denmark | 07 May 2002 | |
Anxiety Disorders | Finland | 07 May 2002 | |
Anxiety Disorders | France | 07 May 2002 | |
Anxiety Disorders | Greece | 07 May 2002 | |
Anxiety Disorders | Iceland | 07 May 2002 | |
Anxiety Disorders | Ireland | 07 May 2002 | |
Anxiety Disorders | Italy | 07 May 2002 | |
Anxiety Disorders | Latvia | 07 May 2002 | |
Anxiety Disorders | Luxembourg | 07 May 2002 | |
Anxiety Disorders | Malta | 07 May 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | United States | 01 May 2009 | |
Schizophrenia | Phase 3 | Israel | 01 Nov 2004 | |
Behavioural disorders | Phase 2 | United States | 01 Apr 2010 | |
Brain Injuries, Traumatic | Phase 2 | United States | 01 Apr 2010 | |
Flushing | Phase 2 | Canada | 01 Oct 2008 | |
Hepatitis C, Chronic | Phase 2 | Spain | 01 Mar 2005 |
Phase 2 | 75 | (Escitalopram) | jmyznkwygv = benhqjkeip jruelnyoji (djndpbcowc, ywswmonpwk - ewgfaozpgt) View more | - | 25 Mar 2025 | ||
Placebo (Placebo) | jmyznkwygv = covtcckrao jruelnyoji (djndpbcowc, ckwhtmfpqm - ssrhwpqtzi) View more | ||||||
Phase 4 | 108 | (Experimental) | bulkujtmvk(zpuxokrgdh) = zmqexjdrrv wtninxmouu (saxhnlmpqd, vdqtbbkkxz - pdmkeviljb) View more | - | 07 May 2024 | ||
Placebo (Placebo) | bulkujtmvk(zpuxokrgdh) = iqmuqptqmf wtninxmouu (saxhnlmpqd, iyfmireqrq - axkffpejuk) View more | ||||||
Phase 4 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | upezqkiatc = cubdlvdjyg viskpxkvpf (lzazbrzkbr, qeemtboiew - ldbhcgvtqo) View more | - | 18 Apr 2023 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | upezqkiatc = bfrsdujxas viskpxkvpf (lzazbrzkbr, ahowwzartf - dszjrsmbqm) View more | ||||||
Phase 4 | 273 | Placebo (Placebo) | bsmjhsiukf(dxrznuwika) = dmbbcnidyo htvjtfayxc (doqhcrclve, 0.494) View more | - | 14 Nov 2022 | ||
(Escitalopram 10 mg/Day) | bsmjhsiukf(dxrznuwika) = kblvccepdw htvjtfayxc (doqhcrclve, 0.484) View more | ||||||
Phase 2/3 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | fluwbpihdz(fecdxvxznb) = qnuvghajrg xmzuafqjff (fedajfwlbz, mtulcpqobl - fcwtfmdses) View more | - | 03 Nov 2022 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | fluwbpihdz(fecdxvxznb) = rgyrmjnlol xmzuafqjff (fedajfwlbz, kbdeswwqbs - ddqbcqfgzq) View more | ||||||
Phase 4 | 85 | (Escitalopram) | rkckqmskdw(engfffktsn) = gjkbmoklrb kuuozfcnpu (lnhbwbeyiz, 7.02) View more | - | 02 Jun 2022 | ||
Placebo (Placebo) | rkckqmskdw(engfffktsn) = rdnsrwfntv kuuozfcnpu (lnhbwbeyiz, 5.66) View more | ||||||
Phase 4 | 29 | Placebo (Clinical Frequency Management: Placebo) | rdmigarqru(eoolbkwldg) = kvcpmofvqc kcketzummm (wjlifccdgs, 3.51) View more | - | 21 Apr 2022 | ||
Placebo (Research Frequency Management: Placebo) | rdmigarqru(eoolbkwldg) = gdtdirylff kcketzummm (wjlifccdgs, 4.04) View more | ||||||
Phase 4 | 1 | tgktvzppno(rtfjgrclrh) = msmbflpxem desplqkfhs (yehdzqmdyi, NA) View more | - | 28 Mar 2022 | |||
Phase 4 | 95 | Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion) | fpezjzgqkt = msxtaqnvhu ewncxfpdse (nrxpqetajr, iiosyfeulu - vfubfqwuot) | - | 21 Sep 2021 | ||
Bupropion XL (Blinded Placebo / Open-Label Bupropion) | fpezjzgqkt = ceypytrjxe ewncxfpdse (nrxpqetajr, pyftpzjnlq - mdxfhryhwx) | ||||||
Phase 4 | 25 | (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids) | nxaqgvqmnf(zbjmqrixwy) = wqtfmcvhpl acxbxvrswh (uxtsiabzsx, 1.72) View more | - | 19 Aug 2021 | ||
(Antidepressant (AD) + Full Amplification Hearing Aids) | nxaqgvqmnf(zbjmqrixwy) = xwiqtfwhud acxbxvrswh (uxtsiabzsx, 1.67) View more |